Drugs / ABBV-295
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07514260 | Mar 2026 → Jan 2027 expected | — | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT07414784 | Feb → Aug 2026 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT07291232 | Nov 2025 → Oct 2026 expected | obesity disorder | AbbVie | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07752979 | Aug 2026 → Mar 2028 expected | obesity disorder | AbbVie | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-09-30 | Gubra A/S | Results Gubra’s partner AbbVie presents detailed Phase 1 data for ABBV-295, a long-acting amylin analog, demonstrating favorable tolerability and pharmacokinetic profile at EASD 2026 gubra.dk ↗
ABBV-295 demonstrated an approximately 11- to 12-day half-life and dose-proportional increases in plasma exposure, supporting evaluation of ABBV-295 at dosing intervals beyond weekly administration, including every-other-week and monthly regimens. |
| 2026-09-30 | Vitae Pharmaceuticals, Inc. | Results AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026 abbvie.com ↗
Detailed findings, to be presented in a short oral presentation, demonstrated an approximately 11- to 12-day half-life and dose-proportional increases in plasma exposure, supporting evaluation of ABBV-295 at dosing intervals beyond weekly administration, including every-other-week and monthly regimens |
| 2026-03-09 | Gubra A/S | Results AbbVie reports Positive Phase 1 Multiple Ascending Dose Results for ABBV-295, a Long-Acting Amylin Analog gubra.dk ↗
Gubra’s partner AbbVie today announced positive topline results from the 12 and 13-weeks Phase 1 Multiple Ascending Dose (MAD) trial showing that ABBV-295 was well tolerated with a dose-dependent significant and clinically meaningful weight loss, compared to placebo. |
| 2026-03-09 | AbbVie | Results AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults abbvie.com ↗
ABBV-295 demonstrated clinically meaningful, dose-dependent reductions in body weight from baseline, over a 12-13-week treatment period. |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-295 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07291232 ↗ |
| Route | Subcutaneous | “subcutaneous doses of ABBV-295” NCT07291232 ↗ |